Can a One-Two punch shrink fibroids better?
NCT ID NCT07754877
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial tests whether adding a chemical injection to microwave ablation improves treatment for uterine fibroids, common non-cancerous tumors that can cause heavy bleeding and pain. Microwave ablation uses heat to destroy fibroid tissue, but blood flow can cool the area and reduce its effectiveness. The study compares the standard microwave ablation alone versus microwave ablation combined with a chemical agent that may block blood flow and enhance the heat effect. Researchers will measure how much the fibroids shrink, symptom improvement, and safety in 248 women.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Microwave ablation combined with lauromacrogol (chemical ablation) versus microwave ablation alone
- What this could lead to
- If the combined approach works, it could offer a more effective, less invasive treatment for uterine fibroids, potentially reducing symptoms and preserving fertility better than current options.
- What could go wrong
- This is a relatively early-stage trial, and the combination may not improve outcomes enough to justify added risks. The heat-sink effect and individual fibroid characteristics could limit the benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 248 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. A definitive diagnosis of uterine fibroids confirmed by magnetic resonance imaging (MRI) and ultrasonography, with the International Federation of Gynecology and Obstetrics (FIGO) classification 0-6; 2. At least one of the following symptoms: menorrhagia, secondary anemia, abdominal/pelvic pain, or compression symptoms; 3. Absence of perimenopausal signs; 4. A safe transabdominal puncture route accessible under imaging guidance. Exclusion Criteria: 1. Suspicion of malignancy on ultrasound or MRI that cannot be ruled out (e.g., uterine sarcoma; uterine fibroids coexisting with cervical, endometrial, or ovarian cancer; or other gynecological malignancies); 2. Uterine fibroids with coexisting adenomyosis; 3. Menstrual, gestational, or lactational period; 4. Uterine fibroids classified as FIGO type 7; 5. Known allergy to alcohol, lauromacrogol, or related sclerosing agents; 6. Absence of a safe percutaneous puncture route (e.g., lesion adherent to critical structures - bowel, bladder, or major vessels - that cannot be safely separated); 7. Uncontrolled acute pelvic inflammatory disease; 8. Significant hepatic, renal, or other major organ dysfunction; 9. Severe coagulopathy, defined as platelet count \<50 × 10⁹/L, prothrombin time \>25 s, or prothrombin activity \<40%; 10. History of other malignancies; 11. Participation in another clinical trial within 1 month prior to informed consent; 12. Any other condition deemed by the investigator to render the subject unsuitable for participation in this trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Microwave ablation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Aerospace center hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can toe exercises straighten young bunions?
- Ultrasound could replace x-ray for checking stomach tubes
- Heart surgery artery line: does it leave a mark on blood flow or hand skills?
- AI plus ultrasound could catch heart and lung decline before it turns critical
- Can sound waves to the spleen alter blood clotting?
- Can AI guide novices to capture clear heart images?